Paper39680587
Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.
Beig M and 6 others. PLoS One, 2024. Cited by 25 papers, by iCite.
Cite this record
ConductScience Library. Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis. Papers, record 39680587. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39680587
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Acinetobacter baumannii | Major topic |
| Carbapenems | Major topic |
| Acinetobacter Infections | Major topic |
| Humans | |
| Anti-Bacterial Agents | |
| Geographic Mapping | |
| COVID-19 | |
| Drug Resistance, Bacterial |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 40261851 | Correction: Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis. | https://conductscience.org/library/papers/40261851 |
Source PubMed
References658
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30473888 | Prevalence of Extended Spectrum Betalactamase (ESBL) and Metallobetalactamase (MBL) Producing Pseudomonas aeruginosa and Acinetobacter baumannii Isolated from Various Clinical Samples. | J Pathog | 2018 | https://conductscience.org/library/papers/30473888 | PubMed |
| 2 | 32494882 | Polymyxin B Heteroresistance and Adaptive Resistance in Multidrug- and Extremely Drug-Resistant Acinetobacter baumannii. | Curr Microbiol | 2020 | https://conductscience.org/library/papers/32494882 | PubMed |
| 3 | 27448835 | High prevalence of extensively drug-resistant and metallo beta-lactamase-producing clinical Acinetobacter baumannii in Iran. | Microb Pathog | 2016 | https://conductscience.org/library/papers/27448835 | PubMed |
| 4 | 36677463 | Carbapenem-Resistant Acinetobacter baumannii: Biofilm-Associated Genes, Biofilm-Eradication Potential of Disinfectants, and Biofilm-Inhibitory Effects of Selenium Nanoparticles. | Microorganisms | 2023 | https://conductscience.org/library/papers/36677463 | PubMed |
| 5 | 31031096 | Clinical characteristics and outcomes of community and hospital-acquired Acinetobacter baumannii bacteremia. | J Microbiol Immunol Infect | 2019 | https://conductscience.org/library/papers/31031096 | PubMed |
| 6 | 32340386 | Acinetobacter baumannii Resistance: A Real Challenge for Clinicians. | Antibiotics (Basel) | 2020 | https://conductscience.org/library/papers/32340386 | PubMed |
| 7 | 27551277 | Carbapenem Resistance in Acinetobacter baumannii and Other Acinetobacter spp. Causing Neonatal Sepsis: Focus on NDM-1 and Its Linkage to ISAba125. | Front Microbiol | 2016 | https://conductscience.org/library/papers/27551277 | PubMed |
| 8 | 35573022 | Microbiological and Clinical Characteristics of Bloodstream Infections in General Intensive Care Unit: A Retrospective Study. | Front Med (Lausanne) | 2022 | https://conductscience.org/library/papers/35573022 | PubMed |
| 9 | 31819549 | Multidrug-Resistant Infections Among Hospitalized Adults With Community-Acquired Pneumonia In An Indonesian Tertiary Referral Hospital. | Infect Drug Resist | 2019 | https://conductscience.org/library/papers/31819549 | PubMed |
| 10 | 36825087 | Virulence potential of multidrug-resistant Acinetobacter baumannii isolates from COVID-19 patients on mechanical ventilation: The first report from Serbia. | Front Microbiol | 2023 | https://conductscience.org/library/papers/36825087 | PubMed |
| 11 | 35571285 | MDR Pathogens Organisms as Risk Factor of Mortality in Secondary Pulmonary Bacterial Infections Among COVID-19 Patients: Observational Studies in Two Referral Hospitals in West Java, Indonesia. | Int J Gen Med | 2022 | https://conductscience.org/library/papers/35571285 | PubMed |
| 12 | 26261812 | Molecular identification of Acinetobacter baumannii isolated from intensive care units and their antimicrobial resistance patterns. | Adv Biomed Res | 2015 | https://conductscience.org/library/papers/26261812 | PubMed |
| 13 | 35820671 | Epidemiological characteristics of carbapenem-resistant Enterobacteriaceae and carbapenem-resistant Acinetobacter baumannii in a tertiary referral hospital in Korea. | Osong Public Health Res Perspect | 2022 | https://conductscience.org/library/papers/35820671 | PubMed |
| 14 | 31318107 | Mutation of CarO participates in drug resistance in imipenem-resistant Acinetobacter baumannii. | J Clin Lab Anal | 2019 | https://conductscience.org/library/papers/31318107 | PubMed |
| 15 | 35948242 | Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016-2018). | J Glob Antimicrob Resist | 2022 | https://conductscience.org/library/papers/35948242 | PubMed |
| 16 | 17307973 | In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. | Antimicrob Agents Chemother | 2007 | https://conductscience.org/library/papers/17307973 | PubMed |
| 17 | 29341954 | Carbapenemase Production of Clinical Isolates Acinetobacter baumannii and Pseudomonas aeruginosa from a Bulgarian University Hospital. | Folia Med (Plovdiv) | 2017 | https://conductscience.org/library/papers/29341954 | PubMed |
| 18 | 21996241 | Acinetobacter baumannii multidrug-resistant strain occurrence in liver recipients with reference to other high-risk groups. | Transplant Proc | 2011 | https://conductscience.org/library/papers/21996241 | PubMed |
| 19 | 27659437 | A 5-year Surveillance Study on Antimicrobial Resistance of Acinetobacter baumannii Clinical Isolates from a Tertiary Greek Hospital. | Infect Chemother | 2016 | https://conductscience.org/library/papers/27659437 | PubMed |
| 20 | 31701463 | The Efficacy of Imipenem Conjugated with Synthesized Silver Nanoparticles Against Acinetobacter baumannii Clinical Isolates, Iran. | Biol Trace Elem Res | 2020 | https://conductscience.org/library/papers/31701463 | PubMed |
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42723758 | Prioritization of antimicrobial resistance surveillance of gram-negative pathogens - a stacked modelling approach. | Wellcome Open Res | 2026 | https://conductscience.org/library/papers/42723758 | PubMed |
| 42353653 | Multiplex PCR-Based Detection of Eight Carbapenemase Genes and Their Clinical Characteristics in Urinary Tract Infections. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42353653 | PubMed |
| 42326428 | Clinical characteristics and risk factor analysis of multidrug-resistant bacterial bloodstream infections in adult acute leukemia patients. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42326428 | PubMed |
| 42192686 | High-Resolution Genomic Surveillance of Carbapenem-Resistant Acinetobacter baumannii: IC-2 Clonal Diversity, Resistance Determinants, and Virulence Signatures. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42192686 | PubMed |
| 41932930 | In silico design of a multiepitope vaccine against antibiotic drug-resistant Acinetobacter baumannii. | Sci Rep | 2026 | https://conductscience.org/library/papers/41932930 | PubMed |
| 41814592 | Plumbagin Disrupts Biofilm Integrity and Resistance Gene Expression in Carbapenem-Resistant Acinetobacter baumannii. | J Microbiol Biotechnol | 2026 | https://conductscience.org/library/papers/41814592 | PubMed |
| 41685899 | Assessment of the revision of the 2025 CLSI breakpoints for the interpretation of minocycline susceptibility for Acinetobacter baumannii complex. | Microbiol Spectr | 2026 | https://conductscience.org/library/papers/41685899 | PubMed |
| 41631835 | Whole-genome analysis of extensively drug-resistant Acinetobacter baumannii isolates from a Peruvian tertiary hospital reveals the emergence of OXA-23-producing ST79 and ST1079 clones. | Microbiol Spectr | 2026 | https://conductscience.org/library/papers/41631835 | PubMed |
| 41594040 | Multidrug-Resistant Acinetobacter baumannii: Resistance Mechanisms, Emerging Therapies, and Prevention-A Narrative Review. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/41594040 | PubMed |
| 41389350 | Genetic diversity and antimicrobial resistance of clinical Acinetobacter baumannii isolates: insights from ERIC typing. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/41389350 | PubMed |
| 41060575 | Antimicrobial potential of compounds from the MMV pandemic response box and COVID box against carbapenem-resistant Acinetobacter baumannii. | Braz J Microbiol | 2025 | https://conductscience.org/library/papers/41060575 | PubMed |
| 41020613 | Clinical characteristics and treatment outcomes of Acinetobacter baumannii bloodstream infections in a setting with high carbapenem susceptibility among isolates. | Microbiol Spectr | 2025 | https://conductscience.org/library/papers/41020613 | PubMed |
| 41007864 | Clinical Implications of Bacteremia Caused by Non-baumannii Acinetobacter Compared with Those of Acinetobacter baumannii Bacteremia. | Biomedicines | 2025 | https://conductscience.org/library/papers/41007864 | PubMed |
| 40650755 | Unravelling the genomic landscape of Acinetobacter baumannii: deep dive into virulence factors, resistance elements, and evolutionary adaptations. | Mol Genet Genomics | 2025 | https://conductscience.org/library/papers/40650755 | PubMed |
| 40444001 | The intricacies of Acinetobacter baumannii: a multifaceted comprehensive review of a multidrug-resistant pathogen and its clinical significance and implications. | Front Microbiol | 2025 | https://conductscience.org/library/papers/40444001 | PubMed |
| 40413665 | Relationship between antibiotic resistance and biofilm-forming capacity with RND efflux pumps expression in clinical Acinetobacter baumannii isolates. | Arch Microbiol | 2025 | https://conductscience.org/library/papers/40413665 | PubMed |
| 40261851 | Correction: Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis. | PLoS One | 2025 | https://conductscience.org/library/papers/40261851 | PubMed |
| 40063635 | Development of a multi-epitope vaccine against Acinetobacter baumannii: A comprehensive approach to combating antimicrobial resistance. | PLoS One | 2025 | https://conductscience.org/library/papers/40063635 | PubMed |
| 39858944 | Clonality and the Phenotype-Genotype Correlation of Antimicrobial Resistance in Acinetobacter baumannii Isolates: A Multicenter Study of Clinical Isolates from Romania. | Microorganisms | 2025 | https://conductscience.org/library/papers/39858944 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39680587
GET https://conductscience.org/api/papers/v1/39680587/references?page=2